Bellicum Pharmaceuticals, Inc. (BLCM)
(Delayed Data from NSDQ)
$3.15 USD
+0.13 (4.30%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.15 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BLCM 3.15 +0.13(4.30%)
Will BLCM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BLCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLCM
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?
BLCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?